Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 24;22(1):111.
doi: 10.1186/s12955-024-02318-y.

Defining the relationship between clinician-rated ECOG performance status and patient-reported health-related quality of life scores in men with metastatic hormone-naïve prostate cancer

Ikenna I Nnabugwu  1   2 , Eric N Obikeze  3 , Chinwe A Nnabugwu  3 , Solomon K Anyimba  4   5 , Okwudili C Amu  4   5 , Okezie M Mbadiwe  4 , Kevin S N Echetabu  4 , Ijeoma L Okoronkwo  3
Affiliations

Defining the relationship between clinician-rated ECOG performance status and patient-reported health-related quality of life scores in men with metastatic hormone-naïve prostate cancer

Ikenna I Nnabugwu et al. Health Qual Life Outcomes. .

Abstract

Background: Performance status and health-related quality of life (HRQoL) are important parameters in the management of metastatic prostate cancer. The clinician-rated Eastern Cooperative Oncology Group performance status (ECOG-PS) may not relate with the patient-reported HRQoL because the later puts into consideration some aspects of health that are not captured by the former. The aim of this study is to define the relationship between clinician-rated ECOG-PS and the patient-reported HRQoL in men with metastatic hormone-naïve prostate cancer (mPCa).

Methods: An analytical cross-sectional study recruiting patients presenting with mPCa in Enugu, southeast Nigeria. Two clinicians agreed on an ECOG-PS score for each study participant who in turn completed the Functional Assessment in Cancer Therapy - Prostate (FACT-P) and the EuroQol EQ-5D-5 L questionnaires with interviewer-assistance where necessary. Other medical information was retrieved from the records. ANOVA and chi-square tests were used to compare available data across ECOG-PS ratings and ordinal logistic regression was used to determine the FACT-P questionnaire items that related significantly with the ECOG-PS scores.

Results: Of the 224 participants (mean age: 70.62 ± 7.34), about 60.7% had ≥ 12years of formal education and 84.9% had ISUP grade ≥ 3 cancer. In all, 22.8%, 55.8%, 21.0% and 0.4% were ECOG-PS 1, ECOG-PS 2, ECOG-PS 3 and ECOG-PS 4 respectively. The mean FACT-P score, health utility index (HUI) and visual analogue scale (VAS) scores were 80.18 ± 17.56, 0.524 ± 0.324 and 60.43 ± 9.91% respectively. The FACT-P score (p = 0.002), HUI (p < 0.001) and VAS score (p < 0.001) varied significantly across the ECOG-PS ratings. Within the FACT-P, only questionnaire items GP3 (p = 0.024) and GP7 (p < 0.001) of the PWB domain, and items GF5 (p = 0.009) and GF6 (p = 0.003) of the FWB domain related strongly with the ECOG-PS categories.

Conclusion: There are indications that HRQoL questionnaire items that have to do with impairment in physical and role functioning relate strongly with ECOG-PS categories.

Keywords: ECOG; EQ-5D-5L; FACT-P; HRQoL; Metastatic prostate cancer; Performance status.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The study was approved by the health research ethics committee of the University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu. Each participant gave a written informed consent. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

References

    1. Nzeyimana I, Nyirimodoka A, Ngendahayo E, Bonane A, Muhawenimana E, Umurangwa F, et al. Diagnosis of advanced prostate cancer at the community level in Rwanda. Int Urol Nephrol. 2021;53:1977–85. 10.1007/s11255-021-02921-8. - PubMed
    1. Ugwumba FO, Nnabugwu II. Prostate cancer characteristics: a descriptive analysis of clinical features at presentation in the last decade in a black African community. Ann Afr Med. 2022;21:153–7. 10.4103/aam.aam_101_20. - PMC - PubMed
    1. Robbins R, Cole R, Ejikeme C, Orstad SL, Porten S, Salter CA, et al. Systematic review of sleep and sleep disorders among prostate cancer patients and caregivers: a call to action for using validated sleep assessments during prostate cancer care. Sleep Med. 2022;94:38–53. 10.1016/j.sleep.2022.03.020. - PMC - PubMed
    1. Kwan EM, Thangasamy IA, Teh J, Alghazo O, Sathianathen NJ, Lawrentschuk N, et al. Navigating systemic therapy for metastatic castration-naïve prostate cancer. World J Urol. 2021;39:339–48. 10.1007/s00345-019-03060-7. - PubMed
    1. Serritella AV, Hussain M. Metastatic hormone-sensitive prostate cancer in the era of doublet and triplet therapy. Curr Treat Options Oncol. 2024;25:293–312. 10.1007/s11864-023-01173-1. - PubMed

LinkOut - more resources